Novel Agents Emerging in the Lung Cancer Pipeline
Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, describes the last decade in lung cancer diagnostics and significant therapeutic advances. He also navigates the emerging classes of drugs that are beginning to make headway in the lung cancer pipeline.
EP: 1.Introduction to Lung Cancer Screening and Treatment
EP: 2.Effective Lung Cancer Screening Leads to Opportunities
EP: 3.What Are the Current Treatment Options in Lung Cancer?
Now Viewing
EP: 4.Novel Agents Emerging in the Lung Cancer Pipeline
EP: 5.Utilizing Patient-Friendly Pathways in Lung Cancer Diagnostics and Treatment
EP: 6.Future Strategies With Lung Cancer Screening
Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, describes the last decade in lung cancer diagnostics and significant therapeutic advances. He also navigates the emerging classes of drugs that are beginning to make headway in the lung cancer pipeline.
Related Videos
Related Content
